Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
12.8 EUR
770.13 M EUR
2.02 B EUR
61.01 M
About ARGENX SE
Sector
Industry
CEO
Tim van Hauwermeiren
Website
Headquarters
Amsterdam
Founded
2008
ISIN
NL0010832176
FIGI
BBG006Z1V3G7
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio b
Argenx Lead as Chugai's Muscle Disease Treatment DisappointsIn a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the
Breakout trade in ARGXArgenx is another biotech stock setting up in a textbook breakout pattern.
Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market.
ARGX still held up well, and will likely continue its advance higher.
$ARGX with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $ARGX after a Positive Under reaction following its earnings release placing the stock in drift D.
ARGX Bullish Trade Setup Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0%
Funds Hol
Will ARGX break out ascending channelWill Argenx be Wall streets next Biotech unicorn? I am extremely bullish!
Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry.
Again great news for Argenx.
01feb2021
launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials
ARGX Buy Signal To Watch .After forming the gap at the market open , NASDAQ:ARGX has succeeded to close above the Red Line around the 206.5 .
IF it succeeds today or in an upcoming day to close with bullish strength considerably above the green line at around the 217 mark ,I think It is likely to continue up to around th
argenx Announces Positive Topline Results from Phase 3 ADAPT TriARGX: argenx SE
2020-05-26 01:00:00
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 1AE is featured.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ARGENX SE EO -,10 stocks are traded under the ticker 1AE.
We've gathered analysts' opinions on ARGENX SE EO -,10 future price: according to them, 1AE price has a max estimate of 983.86 EUR and a min estimate of 572.85 EUR. Watch 1AE chart and read a more detailed ARGENX SE EO -,10 stock forecast: see what analysts think of ARGENX SE EO -,10 and suggest that you do with its stocks.
Yes, you can track ARGENX SE EO -,10 financials in yearly and quarterly reports right on TradingView.
ARGENX SE EO -,10 is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
1AE net income for the last half-year is 799.60 M EUR, while the previous report showed −30.10 M EUR of net income which accounts for 2.76 K% change. Track more ARGENX SE EO -,10 financial stats to get the full picture.
No, 1AE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 5, 2025, the company has 1.6 K employees. See our rating of the largest employees — is ARGENX SE EO -,10 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARGENX SE EO -,10 EBITDA is −54.06 M EUR, and current EBITDA margin is −2.12%. See more stats in ARGENX SE EO -,10 financial statements.
Like other stocks, 1AE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARGENX SE EO -,10 stock right from TradingView charts — choose your broker and connect to your account.